Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

Alvogen Lux Holdings has increased its stake in Alvotech by acquiring 95,000 shares, indicating confidence in the company's future performance. This acquisition reinforces Alvogen Lux Holdings ...

Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This ...

Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This ...

We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to take a look at where Alvotech (NASDAQ:ALVO) stands against the other stocks ...

Alvotech anticipates that potential U.S. tariffs on imported pharmaceuticals will have minimal impact on their product revenues, estimated at less than 1% for 2025. Customers will bear the costs ...

Alvotech has developed a biosimilar of Humira called AVT02, the first-filed biosimilar drug equal in strength to Humira’s latest formulation, which AbbVie markets as a high-concentration, pain ...

Alvotech's stock has dropped significantly due to potential tariffs and ongoing profitability challenges, despite strong revenue growth and a promising biosimilar pipeline. The company's reliance ...

Selardsdi is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...

“With two important biosimilars on the U.S. market and Biologics License Applications for three new biosimilar candidates under FDA review, Alvotech continues to rapidly expand its portfolio of ...

Learn more about whether Alvotech or BioCryst Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.